Longo Umile Giuseppe, Marino Martina, de Sire Alessandro, Ruiz-Iban Miguel A, D'Hooghe Pieter
Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
Research Unit of Orthopaedic and Trauma Surgery, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
Knee Surg Sports Traumatol Arthrosc. 2025 Mar;33(3):1070-1090. doi: 10.1002/ksa.12429. Epub 2024 Sep 5.
The aim of this study is to report and discuss the outcomes of clinical, histological and animal studies exploring the application of bio-inductive collagen implants (BCIs) to partial and full-thickness rotator cuff tears (PT- and FT-RCTs) in addition to reporting on cost-related factors.
Review of literature was performed using the PRISMA guidelines. A systematic electronic literature search was conducted using the CENTRAL, CINAHL, Cochrane Library, EBSCOhost, EMBASE and Google Scholar bibliographic databases. Microsoft Excel was used to create tables onto which extracted data were recorded. Tables were organized based on the research statement formulated using the PICO approach. No statistical analysis was performed.
Nine studies evaluated clinical and MRI outcomes of BCI augmentation for FT-RCTs, seven evaluated similar outcomes when applied to PT-RCTs, two additional studies were case reports and three studies assessed application to FT- and PT-RCTs without stratification of results, one of which also reported on histological data. Two studies reported on histological data alone, and finally, two reported on healthcare costs. BCI augmentation, alone and combined with rotator cuff repair (RCR), displays generally good histological, postoperative clinical and MRI outcomes for PT- and FT-RCT treatment. Recent economic analyses seem to be in favour of the use of this procedure, when selected and applied for appropriate patient populations.
Several studies have shown promising results of BCI application to PT- and FT-RCTs, both concomitantly and independently from RCR. Investigations report promising histological characteristics, improved clinical outcomes, increased tendon thickness, reduced defect size and lower re-tear rates.
Level IV.
本研究旨在报告并讨论临床、组织学和动物研究的结果,这些研究探索了生物诱导性胶原蛋白植入物(BCI)在部分和全层肩袖撕裂(PT-和FT-RCT)中的应用,此外还报告了与成本相关的因素。
使用PRISMA指南进行文献综述。通过CENTRAL、CINAHL、Cochrane图书馆、EBSCOhost、EMBASE和谷歌学术文献数据库进行系统的电子文献检索。使用Microsoft Excel创建表格,将提取的数据记录在表格上。表格根据使用PICO方法制定的研究声明进行组织。未进行统计分析。
九项研究评估了BCI增强治疗FT-RCT的临床和MRI结果,七项研究评估了其应用于PT-RCT时的类似结果,另外两项研究为病例报告,三项研究评估了其应用于FT-和PT-RCT但未对结果进行分层,其中一项还报告了组织学数据。两项研究仅报告了组织学数据,最后两项报告了医疗保健成本。单独使用BCI增强以及与肩袖修复(RCR)联合使用,在治疗PT-和FT-RCT方面通常显示出良好的组织学、术后临床和MRI结果。最近的经济分析似乎支持在为合适的患者群体选择并应用该手术时使用此方法。
多项研究表明,BCI应用于PT-和FT-RCT,无论是与RCR同时使用还是独立使用,都取得了有前景的结果。研究报告显示出有前景的组织学特征、改善的临床结果、增加的肌腱厚度、减小的缺损尺寸和较低的再撕裂率。
四级。